Identification of autoantigens in pediatric opsoclonus-myoclonus syndrome

  title={Identification of autoantigens in pediatric opsoclonus-myoclonus syndrome},
  author={Franz Blaes and Verena F{\"u}hlhuber and Klaus Theo Preissner},
  journal={Expert Review of Clinical Immunology},
  pages={975 - 982}
Pediatric opsoclonus–myoclonus syndrome (OMS) is a rare disease, including eye movement disturbances, muscle jerks, ataxia and developmental disturbances as the main symptoms. In 50% of patients, OMS is associated with a neuroblastoma as a paraneoplastic neurological syndrome. Since autoantibodies have been detected in some patients and OMS patients respond to immunosuppression, an autoimmune etiology has been suspected in OMS. A variety of autoantibodies have been reported in association with… 
Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment
Although the neurological symptoms show a good response, most children continue to show neuropsychological disturbances, and children appear to respond regularly to immunosuppressive treatment.
Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome
Autoantibodies to GluD2 are common in patients with OMAS, bind to surface determinants, and are potentially pathogenic.
Association of Primary Biliary Cirrhosis with Opsoclonus Myoclonus Syndrome
A case of primary biliary cirrhosis that developed Opsoclonus-Myoclonu Syndrome during an exaggeration of disease process which responded well to intravenous corticosteroids and its good response to treatment in this setting is presented.
Paraneoplastic Syndromes in Neuro-ophthalmology.
D diagnosis and therapy of paraneoplastic syndromes presenting with neuro-ophthalmic symptoms remain a challenge, but strategies are evolving and new approaches are on the horizon.
Acute Movement Disorders in Childhood
Common and uncommon causes of acute-onset movement disorders are summarized, focusing on clinical presentation and appropriate diagnostic investigations, to provide a useful clinician’s guide to this expanding field of pediatric neurology.
Paraneoplastic Syndromes in Neuro-Ophthalmology
  • L. Gordon
  • Medicine
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • 2015
The presence of specific antibodies may help confirm the diagnosis of paraneoplastic syndromes and, in some cases, the visual pathway disturbance precedes a diagnosis of malignancy.
Applications Invited for Arthritis & Rheumatology Editor (2015‐2020 Term)
In children than in adults, MRI parameters for prediction of multiple sclerosis in children with acute CNS demyelination: a prospective national cohort study.
Distinct Phenotype Clusters in Childhood Inflammatory Brain Diseases: Implications for Diagnostic Evaluation
To identify distinct clusters of children with inflammatory brain diseases based on clinical, laboratory, and imaging features at presentation, to assess which features contribute strongly to the
Diagnosis and Treatment of Paraneoplastic Syndromes
  • Medicine
  • 2013
• Each speaker will prepare a syllabus that must be submitted through the online submission system. • The length of the syllabus will be no shorter than 4 single spaced pages in essay (not point)
Extracellular RNA as a Versatile DAMP and Alarm Signal That Influences Leukocyte Recruitment in Inflammation and Infection
As a consequence of the viral infection cycle, massive amounts of exRNA are liberated, which can provoke further tissue damage and enhance virus dissemination, and it remains to be investigated whether exRNA may also influence viral infections (including COVID-19).


New Autoantibodies in Pediatric Opsoclonus–Myoclonus Syndrome
The concept of a humoral autoimmune process in the pathogenesis of OMS is supported by specific binding of autoantibodies to the surface of neuroblastoma cells and cerebellar granular neurons.
Autoantigen diversity in the opsoclonus‐myoclonus syndrome
Overall, in the indicated types of OM, frequent and heterogeneous immunity to neuronal autoantigens without a single specific antibody marker of OM is found, and the occasional detection of antibodies to known onconeuronal antigens probably is related to cancer‐induced immunity rather than to OM.
Adult paraneoplastic opsoclonus-myoclonus syndrome associated with antimitochondrial autoantibodies
The first case of SCLC-associated OMS with high titre antimitochondrial antibodies (AMA) in serum and CSF is reported, which is a rare complication of cancer characterised by chaotic, synchronous eye movements, spontaneous muscle jerks, and ataxia.
Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.
Comparing the outcome of neuroblastoma patients with and without OMA, relating to prognostic factors, treatment, and the presence or absence of anti-neuronal antibodies found a significant correlation with lower stage disease compared to more advanced disease.
The immunopharmacology of the opsoclonus-myoclonus syndrome.
Recent clinical and laboratory evidence for the autoimmune theory is surveyed and how some current therapies for OMS may exert their effects through immunomodulation is discussed, providing possible new directions for immunologic research and therapy in OMS.